ArticleThe Analyst2026
Revealing the biomolecular response of glioma cells to helium, carbon and oxygen minibeam radiation therapy using synchrotron-based infrared microspectroscopy.
Article in The Analyst, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combining helium, carbon or oxygen beams with minibeam radiation therapy (MBRT) may benefit the treatment of radioresistant tumours while better protecting healthy tissues from radiation toxicities. In this study, the biomolecular response of glioma cell lines to HeMBRT, CMBRT and OMBRT was evaluated using synchrotron-based Fourier transform infrared microspectroscopy (SR-FTIRM). F98 (rat glioma) and U-87 MG (human glioma) cell lines were subjected to conventional broad beam RT (BB) or MBRT at the Heidelberg Ion-Beam Therapy Centre (Germany). Biomolecular effects were assessed with SR-FTIRM at the MIRAS beamline of the ALBA Synchrotron (Spain). Principal component analysis (PCA) uncovered the spectral alterations due to the different irradiation modalities. In F98 cells, IR signatures in the 1254-1225 cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.